TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in NYHA functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: numbers of patients exposed to gliptin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: improvement of olfaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function tests (PEFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of Patient's Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Negative Inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of cervicovaginal diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: MEI score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic reaction of grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Schirmer Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lissamine Green Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of narcotic analgesics consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Crestal Bone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of colon segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain associated to anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Anxiety Using the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Depression Using the Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High risk sexual behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Composite clinical TB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammogram test completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pap test completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes to Body Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes to Muscle Mass Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes to Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of molecular signatures predictive of response to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing antibody titers to at least one RSV/A strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited local and systemic AEs within 7 days and all AEs within 56 days
Endpoint domain: Adverse events/effects
Primary endpoint: Control and Maintain Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intervention engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes of BMI in kg/m^2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC0-24) for Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the blood glucose concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intrahepatic lipids (IHL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CMAI Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual analog scale (VAS) (rest/movement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of rescue analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Re-arrest count
Endpoint domain: Mortality/survival
Primary endpoint: Conners Teacher Rating Scale (CTRS-L)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Conners Parent Rating Scale (CPRS-L)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: British Ability Scale (BAS) II Word and Digit Span Scales
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Survival (OS) at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of stalk projections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constituents of stalk projections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain level using visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in edema using perimetry (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who maintained adequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Screening Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of RO5479599
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Uptake Value (SUV) of 89ZrRO5479599 Determined by Positron Emission Tomography (PET) Scan Over Regions of Interest (ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of additional needed local anesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retention in care with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Treated Subjects Free of Intra-operative CSF Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unplanned Retreatment of the Original Surgical Site
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of blood volume in small blood vessels to total pulmonary blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Slope of terminal D-3MH/3MH decay curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Class of antibiotic used as prophylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Appetite-regulating hormones (ghrelin, PYY, leptin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Functional independence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Return to work/school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Upward migration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5R-STS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar status of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycosylated A1c (HbA1c) at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycosylated A1c (HbA1c) at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Serum Analyte Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Analyte Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC[0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Analyte Concentration-Time Curve from Time Zero to Infinite Time (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in apnea hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Life (EORTC QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (EORTC QLQ-STO22)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall Survival time
Endpoint domain: Mortality/survival
Primary endpoint: Tokophobia measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Taste sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Value placed upon food
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Head Holding Active Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal in stent lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of lesion coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale (NRS) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrences of post-operative nausea/vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Patient Mortality After Index ICU Admission
Endpoint domain: Mortality/survival
Primary endpoint: Detection of primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Viral AUC from nasal swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Target limb major amputation
Endpoint domain: Mortality/survival
Primary endpoint: 6-month progression-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Events of acute myocardial infarction-associated arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Continuous Nicotine Vaping Abstinence From Week 9 Through End of Treatment (Week 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Continuous Nicotine Vaping Abstinence From Week 9 Through End of Follow-up (Week 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Vaping Abstinence in Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Recovery of Level of Consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in brain glucose transport capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Progression of Brain Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Tumor Progression (TTP)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of SCORing Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Risk to drug exposition in utero
Endpoint domain: Adverse events/effects
Primary endpoint: decreased peak direct bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of mother-to-child transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of hepatitis flare during pregnancy and postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Successful Completion of Pelvic Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STN 8-30 Hz mean power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score Adaptive Behavior Assessment System (ABASII)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total score Social Responsiveness Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postspinal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in TNF-alpha production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL-1-beta production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL-6 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL-8 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of distribution of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Latency to Persistent Sleep (LPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Pain severity at rest, night and forced wrist extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated tennis elbow evaluation (PRTEE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability profiles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of clinical hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in emotional skills related to emotional regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in emotional skills related to stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in emotional skills related to positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in emotional skills related to healthy life habits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in emotional skills related to perception of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in emotional skills related to glycosylated index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Needs and difficulties encountered by parents
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: vaginal bleeding and spotting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical diagnosis accuracy of colorectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: StO2 performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weekly blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolism markers (GH, IGF-I, FFA, glucose, insulin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (area under the curve) for metabolism markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Overall KOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Women With Triage Pap Smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's experiences of pregnancy loss aftercare
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Reaching the Targeted LDL-C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification rate of the external branch of the superior laryngeal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of immediate-onset systemic allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: PGA Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-month Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Survival for at least 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Acceptable quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in the metabolic fingerprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carotid plaque prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in BOLD signal in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number and Seriousness of Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Responder by Independent Rater's Assessment at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRNT (Subtype A) GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neural changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation of SPECT/CT findings with tumor histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mortality rate at day 30
Endpoint domain: Mortality/survival
Primary endpoint: CXCL10 in Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CXCL10 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission of Ulcerative Colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Acne Scarring Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the Plasma Concentration versus Time Curve (AUC) of fludarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-Corrected Visual Acuity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of KOOS Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reflex volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Gastroduodenal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in International Co-operative Ataxia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of FIT
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Log change in quantitative HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate after 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Changes in pre-bronchodilator forced expiratory volume in first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quadriceps muscle fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Midazolam - cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atorvastatin - cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam - AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atorvastatin - AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam - AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atorvastatin - AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes